A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

被引：11
|
作者：
Shabani, M. [1 ]
Ehdaei, B. Sadegh [2 ]
Fathi, F. [3 ]
Dowran, R. [1 ]
机构：
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran
[2] Kashan Univ Med Sci, Fac Med, Microbiol & Immunol Dept, Kashan, Iran
[3] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran
来源：
NEW MICROBES AND NEW INFECTIONS | 2021年 / 42卷
关键词：
COVID-19; daclatasvir; HCV; SARS-CoV-2; sofosbuvir; HEPATITIS-C VIRUS; HCV GENOTYPE 1; PLUS SOFOSBUVIR; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; INFECTION; EPIDEMIOLOGY; RESISTANCE; INHIBITOR; EFFICACY;
D O I：
10.1016/j.nmni.2021.100895
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. (c) 2021 The Authors. Published by Elsevier Ltd.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
    Yang, Chih-Jen
    Wei, Yu-Jui
    Chang, Hsu-Liang
    Chang, Pi-Yu
    Tsai, Chung-Chen
    Chen, Yen-Hsu
    Hsueh, Po-Ren
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (01) : 27 - 36
  • [2] Pharmacological and nonpharmacological studies on coronavirus disease 2019: A mini-review of the recent evidence
    Bahmani, Amir Hossein Alizadeh
    Hoorang, Mehdi
    Hosseini, Sheida
    Eskandari, Mehrnoosh
    Shayestehfard, Kiana
    Shekoohi, Mahyar
    Hatami-Mazinani, Nazafarin
    Afifi, Saba
    Sabzghabaee, Ali Mohammad
    Peymani, Payam
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (04) : 175 - 180
  • [3] The Use of Cyclodextrin or its Complexes as a Potential Treatment Against the 2019 Novel Coronavirus: A Mini-Review
    Fatmi, Sofiane
    Taouzinet, Lamia
    Skiba, Mohamed
    Iguer-Ouada, Mokrane
    CURRENT DRUG DELIVERY, 2021, 18 (04) : 382 - 386
  • [4] Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
    Zhu, Ying
    Sharma, Lokesh
    Chang, De
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease
    Moustafa, Ahmed
    Abdallah, Mohamed
    Akel, Wafaa El
    Wahed, Sherif
    Alem, Shereen Abdel
    Esmat, Gamal
    EGYPTIAN LIVER JOURNAL, 2024, 14 (01)
  • [6] Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
    Sulkowski, Mark S.
    Flamm, Steve
    Kayali, Zeid
    Lawitz, Eric J.
    Kwo, Paul
    McPhee, Fiona
    Torbeyns, Anne
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip D.
    Linaberry, Misti
    LIVER INTERNATIONAL, 2017, 37 (06) : 836 - 842
  • [7] Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
    Xue, Yan
    Zhang, Li-Xin
    Wang, Lei
    Li, Tao
    Qu, Yun-Dong
    Liu, Feng
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (32) : 5969 - 5976
  • [8] Ivermectin: a mini-review
    Johnson-Arbor, Kelly
    CLINICAL TOXICOLOGY, 2022, 60 (05) : 571 - 575
  • [9] Histopathologic Findings of Coronavirus in Lung: A Mini-Review
    Geramizadeh, Bita
    Marzban, Mahsa
    CLINICAL PATHOLOGY, 2020, 13
  • [10] Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis
    Ismail, Waleed A.
    Yousef, Ayman E.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (08) : 1025 - 1029
12345